Meeting Impression | Preventing CVD in Patients with T2DMMay 3, 2018 - Ljubljana, Slovenia
See below to download the Meeting Impression
This educational program was held during Europrevent 2018 in Ljubljana, Slovenia. Richard Hobbs, Diederick Grobbee and Lars Rydén discussed the association between type 2 diabetes (T2DM) and cardiovascular disease (CVD) and stressed the importance of CV risk management in these patients in primary care. Traditional therapies to reduce CV risk and the need for novel approaches beyond glucose control to prevent CVD in T2DM patients were discussed. The presenters explained potential mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and presented results from recent CV outcome trials in T2DM patients. Finally, practical implications of these insights on treatment and prevention strategies in T2DM patients with high CV risk were proposed.
This is a summary of the PACE symposium entitled 'Preventing Cardiovascular Disease in Patients with T2DM – How to apply novel outcome data with GLP-1RA to clinical practice', held during EuroPrevent in Ljubljana, Slovenia, on May 3, 2018.
The educational objectives of the symposium were to:
Understand the relation between T2DM & Cardiovascular Disease
Identify the needs for novel approaches targeting T2DM in cardiovascular prevention
Explore results from recent cardiovascular outcome trials (CVOT) in T2DM
Discuss potential mechanisms and multifactorial effects of GLP-1 receptor agonists contributing to cardiovascular benefits
Review results from recent GLP1 RA outcomes trials, such as LEADER on CV and microvascular outcomes
Discuss practical implications from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM
Prof. Richard Hobbs (Oxford, U)K: The cardiovascular challenge for primary care in diabetes
Prof. Diederick Grobbee (Utrecht, The Netherlands): Diabetes: How to reduce risk from a cardiovascular perspective?
Prof. Lars Rydén (Stockholm, Sweden): Practical management of cardiovascular risk: Lessons from latest diabetes trials
The symposium was supported by an unrestricted educational grant from Novo Nordisk.